Skip to main content

Table 2 Baseline characteristics and demographics

From: A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma

 

Summary statistic

Retrieval of 2 Year OS data

Age (years)

 Mean (sd)

63.3 (13.0)

 

  < 40 years

53 (5.8%)

41 (77.4%)

 40–60 years

256 (28.1%)

211 (82.4%)

  > 60 years

601 (66.0%)

499 (83.0%)

Body weight (kg)

 Mean (sd)

80.9 (17.8)

 

  < 70 kg

246 (27.0%)

199 (80.9%)

 70–90 kg

412 (45.3%)

349 (84.7%)

  > 90 kg

252 (27.7%)

203 (80.6%)

Gender

 Female

271 (29.9%)

221 (81.6%)

 Male

635 (70.1%)

528 (83.3%)

ECOG performance status

 Active

351 (38.7%)

293 (83.5%)

 Restricted

468 (51.7%)

65 (90.3%)

 Self-care capable

73 (8.1%)

379 (81.0%)

 Limited self-care capable

13 (1.4%)

11 (84.6%)

 Disabled

1 (0.1%)

1 (100%)

M Status

 M1a (distant skin, subcutaneous or nodal metastases)

74 (8.2%)

63 (85.2%)

 M1b (lung metastases)

156 (17.2%)

124 (79.5%)

 M1c (All other visceral metastases or any distant metastases with elevated serum LDH)

676 (74.6%)

562 (83.3%)

Previous brain metastases

 No

644 (71.1%)

517 (80.3%)

 Yes

262 (28.9%)

232 (88.9%)

Treatment naïve

 No

333 (36.7%)

278 (83.7%)

 Yes

573 (63.3%)

471 (82.2%)

Hospital

 Private

301 (35.6%)

242 (80.1%)

 Public

544 (64.4%)

456 (84.0%)

Community

 Rural

199 (23.5%)

169 (84.9%)

 Urban

647 (76.5%)

529 (81.9%)